[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 45, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Florian  Brand", "age": 36, "title": "Co-Founder, MD & CEO", "yearBorn": 1987, "fiscalYear": 2022, "totalPay": 835442, "exercisedValue": 0, "unexercisedValue": 9709600}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 54, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 834150, "exercisedValue": 0, "unexercisedValue": 457481}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Raven Ph.D.", "title": "Senior Vice President of Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frank  Stegert", "age": 42, "title": "Vice President of Investment & Venture Management", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett", "age": 42, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "title": "Senior Vice President of Early Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sahil V. Kirpekar M.D.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.17, "dayLow": 2.02, "dayHigh": 2.2803, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.17, "regularMarketDayLow": 2.02, "regularMarketDayHigh": 2.2803, "beta": 0.977, "forwardPE": -2.6623378, "volume": 1173475, "regularMarketVolume": 1173475, "averageVolume": 1603941, "averageVolume10days": 965450, "averageDailyVolume10Day": 965450, "bid": 2.04, "ask": 2.07, "bidSize": 200, "askSize": 200, "marketCap": 343196640, "fiftyTwoWeekLow": 1.025, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 1092.9829, "fiftyDayAverage": 1.9904, "twoHundredDayAverage": 1.6335, "currency": "USD", "enterpriseValue": 183993104, "floatShares": 127008533, "sharesOutstanding": 167412992, "sharesShort": 5901316, "sharesShortPriorMonth": 5205386, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0353, "heldPercentInsiders": 0.0999, "heldPercentInstitutions": 0.28059998, "shortRatio": 2.64, "shortPercentOfFloat": 0.0462, "impliedSharesOutstanding": 167412992, "bookValue": 1.463, "priceToBook": 1.4012302, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -40224000, "trailingEps": -0.25, "forwardEps": -0.77, "enterpriseToRevenue": 585.965, "enterpriseToEbitda": -1.509, "52WeekChange": 0.059701443, "SandP52WeekChange": 0.22379243, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ATAI", "underlyingSymbol": "ATAI", "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "firstTradeDateEpochUtc": 1624023000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8699f3bf-7398-34d0-b0ba-129948e2583d", "messageBoardId": "finmb_710359021", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.05, "targetHighPrice": 21.0, "targetLowPrice": 5.1, "targetMeanPrice": 10.68, "targetMedianPrice": 8.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 179256992, "totalCashPerShare": 1.08, "ebitda": -121952000, "totalDebt": 21542000, "quickRatio": 8.996, "currentRatio": 9.224, "totalRevenue": 314000, "debtToEquity": 8.817, "revenuePerShare": 0.002, "returnOnAssets": -0.25518999, "returnOnEquity": -0.17211, "freeCashflow": -37168376, "operatingCashflow": -84118000, "revenueGrowth": -0.526, "grossMargins": 1.0, "operatingMargins": -1864.8333, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]